FDA clinical trials

FDA clinical trials

In the past months we’ve seen the approval of several drugs with limited data. Possibly this is the ‘natural’ consequence of both the Fast Track Designation and the Adaptative Pathway solutions that have been accepted. Though there is clear benefit in accelerating promising developments, we should not overlook two major issues: first, HTA bodies and the administrations they represent are not convinced with this looser approach, not to say some of the national Drug Agencies that are not willing to deal with provisional data; second, and most important, we may now start asking FDA and EMA why did they approve development plans everyone knew would not be accepted for access purposes. It has been argued that HTA bodies delayed access to medicines. We may discuss to which extent this is true, but should also be discussed is the frustration and economic loses a flawed albeit accepted development programme inflicts to...
XXXVII Jornadas de economía de la salud

XXXVII Jornadas de economía de la salud

Taking part in the XXXVII Jornadas de economía de la salud. The days 6th to 8th of September of 2017, in Barcelona, the societies AES and SEE, two of the founders of SESPAS, has organised this congress with the aim of creating a scientific joint meeting to build up, with the mainstream of different topics proposed, an alliance between the different organizations that has come to the workshop. This congress tries to accompany the process of interconnecting the European and worldwide public health networks. And, putting the Spanish public health and health administration on the map. Topics like global warming, social inequality related with health, education, vertical social mobility or big data are covered during the different boards that have took place in this congress. As we know, health problems of the population are complex, with many different causes and effects, that requires a multidisciplinary work; epidemiology, the economy, the healthcare management, environmental health, among others. Those questions have been exposed during the workshop to be able to analyse the problems and solutions of the public health. Specifically, Dr. Sola Morales has participated in the pharmaceutical policies board exposing the topic: Has OMP legislation been successful: an empirical analysis. The final program is available in this web...